REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
REGENXBIO announced the first patient dosed in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec for diabetic retinopathy, triggering a $100 million milestone payment from partner AbbVie. The pivotal study is evaluating the one-time gene therapy in patients with non-proliferative diabetic retinopathy without center-involved diabetic macular edema, targeting a primary endpoint of improvement on the diabetic retinopathy severity scale at one year.
Key figures
- Drug Name
- Surabgene Lomparvovec (sura-vec, ABBV-RGX-314)
- Phase Of Trial
- Phase IIb/III
- Dose level
- 1.0x10(12) genome copies (GC)/eye
- Trial name
- NAAVIGATE
- Milestone payment usd
- 100000000
- Trial enrollment target
- 135
- Atmosphere ascend data date
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.